Study Stopped
Low subject enrollment due to obseleted product.
Talent Converter Post-Approval Study
1 other identifier
observational
20
0 countries
N/A
Brief Summary
The primary endpoint is successful secondary endovascular treatment with the Talent Converter stent graft of subjects having received prior endovascular repair of infrarenal abdominal aortic or aortoiliac aneurysms using the Talent or AneuRx Bifurcated Stent Grafts, in which there is inadequate proximal fixation, seal, overlapping of modular components or unattainable contralateral limb cannulation. Treatment success is defined as a composite of successful vessel access, successful insertion of the delivery system, successful deployment of the Converter stent graft at the intended treatment site and absence of Type I endoleak at the 1 month follow-up visit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2010
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedFirst Submitted
Initial submission to the registry
April 29, 2010
CompletedFirst Posted
Study publicly available on registry
May 24, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
September 29, 2017
CompletedResults Posted
Study results publicly available
May 28, 2019
CompletedOctober 29, 2021
October 1, 2021
3.2 years
April 29, 2010
February 7, 2019
October 27, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Subjects With Successful Secondary Endovascular Treatment
The outcome measure is successful secondary endovascular treatment with the Talent Converter stent graft where treatment success is defined as successful vessel access, successful insertion of the delivery system, successful deployment of the Converter stent graft at the intended treatment site and absence of Type I endoleak at the 1 month follow-up visit.
30 days
Study Arms (1)
Participants with Successful Secondary Endovascular Treatment
Interventions
All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
Eligibility Criteria
All subjects who are treated with the Talent Converter Stent Graft according to the indications for use
You may qualify if:
- Subjects in whom a vessel access procedure was/will be performed with the attempted introduction of the Talent Converter Stent Graft for use according to the indications for use in the Instructions for Use (IFU) 0-365 days prior to enrollment.
- Subjects who are able to understand the nature of the study and give voluntary informed consent.
- Subjects who are available for follow-up visits.
- Subjects 18 years of age or older.
You may not qualify if:
- Subjects in whom an attempted treatment was/will be performed with the Talent Converter Stent Graft other than (i.e., primary AUI) as a secondary endovascular intervention for patients having received prior endovascular repair with either a Talent or AneuRx bifurcated stent graft.
- Subjects in whom an attempted treatment was/will be performed with the Talent Converter Stent Graft as a secondary endovascular intervention for patients having received prior endovascular repair with a bifurcated stent graft other than (i.e., Cook Zenith or Gore Excluder) a Talent or AneuRx bifurcated stent graft.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
FDA allowed for early termination of the Talent Converter PAS because the device is no longer being manufactured, and exsisting inventory of the device has since expired, thus no statistical conclusions will be derived due to low enrollment.
Results Point of Contact
- Title
- Rianna Rapson
- Organization
- Medtronic
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 29, 2010
First Posted
May 24, 2010
Study Start
April 1, 2010
Primary Completion
June 1, 2013
Study Completion
September 29, 2017
Last Updated
October 29, 2021
Results First Posted
May 28, 2019
Record last verified: 2021-10